You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Ibrutinib and novel BTK inhibitors in clinical development
|
|---|---|
| Published in |
Journal of Hematology & Oncology, August 2013
|
| DOI | 10.1186/1756-8722-6-59 |
| Pubmed ID | |
| Authors |
Akintunde Akinleye, Yamei Chen, Nikhil Mukhi, Yongping Song, Delong Liu |
| Abstract |
Small molecule inhibitors targeting dysregulated pathways (RAS/RAF/MEK, PI3K/AKT/mTOR, JAK/STAT) have significantly improved clinical outcomes in cancer patients. Recently Bruton's tyrosine kinase (BTK), a crucial terminal kinase enzyme in the B-cell antigen receptor (BCR) signaling pathway, has emerged as an attractive target for therapeutic intervention in human malignancies and autoimmune disorders. Ibrutinib, a novel first-in-human BTK-inhibitor, has demonstrated clinical effectiveness and tolerability in early clinical trials and has progressed into phase III trials. However, additional research is necessary to identify the optimal dosing schedule, as well as patients most likely to benefit from BTK inhibition. This review summarizes preclinical and clinical development of ibrutinib and other novel BTK inhibitors (GDC-0834, CGI-560, CGI-1746, HM-71224, CC-292, and ONO-4059, CNX-774, LFM-A13) in the treatment of B-cell malignancies and autoimmune disorders. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 239 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | <1% |
| United Kingdom | 1 | <1% |
| Unknown | 236 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 52 | 22% |
| Student > Ph. D. Student | 35 | 15% |
| Student > Bachelor | 35 | 15% |
| Student > Master | 32 | 13% |
| Other | 20 | 8% |
| Other | 26 | 11% |
| Unknown | 39 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 49 | 21% |
| Agricultural and Biological Sciences | 41 | 17% |
| Chemistry | 38 | 16% |
| Biochemistry, Genetics and Molecular Biology | 32 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 17 | 7% |
| Other | 21 | 9% |
| Unknown | 41 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 March 2021.
All research outputs
#1,838,468
of 22,780,967 outputs
Outputs from Journal of Hematology & Oncology
#116
of 1,189 outputs
Outputs of similar age
#17,000
of 198,524 outputs
Outputs of similar age from Journal of Hematology & Oncology
#1
of 14 outputs
Altmetric has tracked 22,780,967 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,189 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.7. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 198,524 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.